Autoimmune Polyendocrinopathies (Schmidt Syndrome) Summary

76 relevant articles (4 outcomes, 3 trials/studies) found for this Disease

Description: Autoimmune diseases affecting multiple endocrine organs. Type I is characterized by childhood onset and chronic mucocutaneous candidiasis (CANDIDIASIS, CHRONIC MUCOCUTANEOUS), while type II exhibits any combination of adrenal insufficiency (ADDISON'S DISEASE), lymphocytic thyroiditis (THYROIDITIS, AUTOIMMUNE;), HYPOPARATHYROIDISM; and gonadal failure. In both types organ-specific ANTIBODIES against a variety of ENDOCRINE GLANDS have been detected. The type II syndrome differs from type I in that it is associated with HLA-A1 and B8 haplotypes, onset is usually in adulthood, and candidiasis is not present.

Also Known As: Schmidt Syndrome; Schmidt's Syndrome; Autoimmune Polyendocrinopathy; Polyendocrinopathies, Autoimmune; Autoimmune Polyglandular Syndrome Type I Show All >>

Key Drugs and Agents for Autoimmune Polyendocrinopathies

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:

Antibodies : 1 outcome in 9 results : IBA
Thyroxine (Levothyroxine) : 1 outcome in 3 results : FDA 14 Generic
Ketoconazole (Nizoral) : 1 outcome in 2 results : FDA 20 Generic
Hydrocortisone (Cortisol) : 1 outcome in 2 results : FDA 176 Generic
Hormones : 1 outcome in 2 results : IBA
Thyrotropin (Thyroid-Stimulating Hormone) : 1 outcome in 1 result : FDA 1
Cortisone : 1 outcome in 1 result : IBA
rituximab (Mabthera) : 1 outcome in 1 result : FDA 3
Autoantibodies : 1 study in 12 results : IBA
Autoantigens : 1 study in 5 results : IBA

Show All >>

Diseases Related to Autoimmune Polyendocrinopathies

Show All >>

Key Therapies for Autoimmune Polyendocrinopathies

Efficacy Chart >>